The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing

The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing

The only licensed vaccine against tuberculosis (TB), bacille Calmette–Guérin (BCG), protects against severe extrapulmonary forms of TB but is virtually ineffective against the most prevalent form of the disease, pulmonary TB. BCG was genetically modified at the Max Planck Institute for Infection Bio...

Full description

Bibliographic Details
Main Authors: Natalie E. Nieuwenhuizen, Prasad S. Kulkarni, Umesh Shaligram, Mark F. Cotton, Cyrill A. Rentsch, Bernd Eisele, Leander Grode, Stefan H. E. Kaufmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-09-01
Series:Frontiers in Immunology
Subjects:
tuberculosis
bacille Calmette–Guérin
VPM1002
vaccine
listeriolysin
immune response
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.01147/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2017.01147/full

Similar Items